Research progress about TyK2 inhibitor deucravacitinib for the treatment of systemic lupus erythematosus

ZHAO Yue; ZHONG Xue; YANG Zhao

doi:10.6039/j.issn.1001-0408.2023.12.23

您当前的位置：

首页 >

文章列表页 >

Research progress about TyK2 inhibitor deucravacitinib for the treatment of systemic lupus erythematosus

更新时间：2025-09-27

- Research progress about TyK2 inhibitor deucravacitinib for the treatment of systemic lupus erythematosus
- ZHONGGUO YAOFANG Vol. 34, Issue 12, Pages: 1529-1531(2023)
- 作者机构：
  
  1.北京大学人民医院药学部，北京　100044
  2.北京大学药学院，北京　100191
  3.北京大学第一医院科研处，北京　100034
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.12.23
  CLC： R969;R967
- Received：10 March 2023，
  
  Revised：2023-05-06，
  
  Accepted：25 May 2023，
  
  Published：30 June 2023
- 稿件说明：
移动端阅览
赵玥,钟雪,杨照.TyK2抑制剂deucravacitinib治疗系统性红斑狼疮的研究进展[J].中国药房,2023,34(12):1529-1531.

ZHAO Yue,ZHONG Xue,YANG Zhao.Research progress about TyK2 inhibitor deucravacitinib for the treatment of systemic lupus erythematosus[J].ZHONGGUO YAOFANG,2023,34(12):1529-1531.
赵玥,钟雪,杨照.TyK2抑制剂deucravacitinib治疗系统性红斑狼疮的研究进展[J].中国药房,2023,34(12):1529-1531. DOI： 10.6039/j.issn.1001-0408.2023.12.23.

ZHAO Yue,ZHONG Xue,YANG Zhao.Research progress about TyK2 inhibitor deucravacitinib for the treatment of systemic lupus erythematosus[J].ZHONGGUO YAOFANG,2023,34(12):1529-1531. DOI： 10.6039/j.issn.1001-0408.2023.12.23.

摘要

deucravacitinib是一种选择性酪氨酸激酶2抑制剂，对于各种免疫系统疾病均显示出一定的治疗潜力，其用于系统性红斑狼疮（SLE）目前还处在临床试验阶段。deucravacitinib口服给药易吸收，并可在24 h内引起药效学效应。与安慰剂比较，治疗第32周时，deucravacitinib组患者符合SLE反应指数4的比例更高，且在英国狼疮评估小组综合狼疮评估、皮肤红斑狼疮疾病面积和严重程度指数50、狼疮低疾病活动状态和活动、肿胀及压痛关节计数方面的反应率也更高。安全性方面，deucravacitinib组皮疹、痤疮等不良事件发生率较高，但仍需进一步观察。目前，已有更多研究正在对deucravacitinib治疗SLE的有效性和安全性进行评估，期待更多数据验证deucravacitinib的治疗潜力。

Abstract

Deucravacitinib is a selective tyrosine kinase 2 inhibitor. It has shown certain therapeutic potential for various immune system diseases， and its use in systemic lupus erythematosus （SLE） is currently in the clinical trial stage. Deucavacitinib is easily absorbed by oral administration and can cause pharmacological effects within 24 hours. Compared with placebo， after 32 weeks of treatment， patients in the deucravacitinib group who meet the SLE response index 4 have a higher proportion， and a higher response rate in the British Isles Lupus Assessment Group’s comprehensive lupus assessment， cutaneous lupus erythematosus disease area and severity index of 50， low disease activity status， and activity， swelling， and tenderness joint counts. In terms of safety， the incidence of adverse events such as rash and acne is higher in the deucravacitinib group than placebo group， but further observation was still needed. At present， more studies are evaluating the cost-effectiveness and safety of deucravatinib in the treatment of SLE， with the expectation of more data validation of deucravatinib’s therapeutic potential.

关键词

Keywords

references

TANAKA Y . Systemic lupus erythematosus [J ] . Best Pract Res Clin Rheumatol ， 2023 ： 101814 .

FORTUNA G ， BRENNAN M T . Systemic lupus erythematosus：epidemiology，pathophysiology，manifestations，and management [J ] . Dent Clin North Am ， 2013 ， 57 （ 4 ）： 631 - 655 .

KIRIAKIDOU M ， CHING C L . Systemic lupus erythematosus [J ] . Ann Intern Med ， 2020 ， 172 （ 11 ）： ITC81 - ITC96 .

MORAND E ， PIKE M ， MERRILL J T ， et al . Deucravacitinib，a tyrosine kinase 2 inhibitor，in systemic lupus erythematosus：a phase Ⅱ，randomized，double-blind，placebo-controlled trial [J ] . Arthritis Rheumatol ， 2023 ， 75 （ 2 ）： 242 - 252 .

NAKAYAMADA S ， TANAKA Y . Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus [J ] . Expert Rev Clin Immunol ， 2022 ， 18 （ 3 ）： 245 - 252 .

CATLETT I M ， ARAS U ， HANSEN L ， et al . First-in-human study of deucravacitinib：a selective，potent，allosteric small-molecule inhibitor of tyrosine kinase 2 [J ] . Clin Transl Sci ， 2023 ， 16 （ 1 ）： 151 - 164 .

Deucravacitinib [J ] . Am J Health Syst Pharm ， 2023 ， 80 （ 1 ）： e4 - e7 .

SAMUEL C ， CORNMAN H ， KAMBALA A ， et al . A review on the safety of using JAK inhibitors in dermato-logy：clinical and laboratory monitoring [J ] . Dermatol Ther ， 2023 ， 13 （ 3 ）： 729 - 749 .

NAPOLITANO M ， RUGGIERO A ， FONTANELLA G ， et al . New emergent therapies for atopic dermatitis：a review of safety profile with respect to female fertility，pregnancy，and breastfeeding [J ] . Dermatol Ther ， 2021 ， 34 （ 1 ）： e14475 .

ZUCCHI D ， ELEFANTE E ， SCHILIRÒ D ， et al . One year in review 2022：systemic lupus erythematosus [J ] . Clin Exp Rheumatol ， 2022 ， 40 （ 1 ）： 4 - 14 .

FORMAN S B ， PARISER D M ， POULIN Y ， et al . TYK2/JAK1 inhibitor PF-06700841 in patients with plaque psoriasis：phase Ⅱa，randomized，double-blind，placebo-controlled trial [J ] . J Invest Dermatol ， 2020 ， 140 （ 12 ）： 2359 - 2370.e5 .

Views

255

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰